Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LP-284 by Lantern Pharma for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
LP-284 is under clinical development by Lantern Pharma and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According...
LP-284 by Lantern Pharma for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
LP-284 is under clinical development by Lantern Pharma and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According...
LP-284 by Lantern Pharma for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
LP-284 is under clinical development by Lantern Pharma and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
LP-284 by Lantern Pharma for Mantle Cell Lymphoma: Likelihood of Approval
LP-284 is under clinical development by Lantern Pharma and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...
LP-284 by Lantern Pharma for Solid Tumor: Likelihood of Approval
LP-284 is under clinical development by Lantern Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
LP-284 by Lantern Pharma for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
LP-284 is under clinical development by Lantern Pharma and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...